Replies to post #112361 on Amarin Corp Plc (AMRN)

[mrmainstreet]

Benny thanks for posting that comment from IR. Very interesting.

[sts66]

Given what we know about the safety profile of Vascepa and give our desire to capture a robust trial results, neither we nor FDA recommended adding a formal futility analysis to the interim looks in REDUCE-IT."

Wait a second - original R-IT SPA was formalized in 2011 or earlier - so if FDA believed there was no safety issue why the hell didn't they squash the comments from the ANCHOR Adcom panel about potential bleeding problems?!?